Sophia Genetics announced that Hopital Saint-Louis, located in Paris, has implemented the Sophia DDM Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation is an expansion of its existing work with Sophia Genetics. The implementation of the Sophia DDM Platform aims to help the Cellular Biology Department expedite its research and increase its ability to provide data-driven care to patients with MPN. The Sophia DDM Platform is a NGS-based application that uses AI to efficiently analyze and interpret raw NGS data for researchers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SOPH:
- SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference
- Sophia Genetics expands work with CHU de Nimes
- Sophia Genetics initiated with an Outperform at RBC Capital
- Sophia Genetics expands relationship with largest health center in Italy
- SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023
